2014
DOI: 10.1074/jbc.r113.529156
|View full text |Cite
|
Sign up to set email alerts
|

Small Molecule Screening in Human Induced Pluripotent Stem Cell-derived Terminal Cell Types

Abstract: A need for better clinical outcomes has heightened interest in the use of physiologically relevant human cells in the drug discovery process. Patient-specific human induced pluripotent stem cells may offer a relevant, robust, scalable, and cost-effective model of human disease physiology. Small molecule high throughput screening in human induced pluripotent stem cellderived cells with the intent of identifying novel therapeutic compounds is starting to influence the drug discovery process; however, the use of … Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1

Citation Types

0
35
0

Year Published

2014
2014
2021
2021

Publication Types

Select...
5
2

Relationship

0
7

Authors

Journals

citations
Cited by 38 publications
(35 citation statements)
references
References 98 publications
0
35
0
Order By: Relevance
“…Assay quality can be determined by the Z′ factor, which is a statistical measure that combines assay robustness with the variability of signal. Z′ > 0.5 is optimal, although this applies only to assays with one time point (112). Many platforms track and quantify cells (74, 117).…”
Section: Discussionmentioning
confidence: 99%
See 2 more Smart Citations
“…Assay quality can be determined by the Z′ factor, which is a statistical measure that combines assay robustness with the variability of signal. Z′ > 0.5 is optimal, although this applies only to assays with one time point (112). Many platforms track and quantify cells (74, 117).…”
Section: Discussionmentioning
confidence: 99%
“…Phenotypic assays can identify effects in complex systems, even in a disease setting in which the biology is not fully understood. This may be particularly suitable in iPSC-derived systems that model NDDs, given that much of the etiology in NDDs is unresolved, involves complex interactions, and often has multiple cellular phenotypes (109112). …”
Section: Assay Developmentmentioning
confidence: 99%
See 1 more Smart Citation
“…In the second minireview, Sandra J. Engle and Fabien Vincent discuss "small molecule screening in human induced pluripotent stem cell-derived terminal cell types" (2). Because hiPSCs offer a means to generate genetically defined cellular disease models, there is tremendous potential in using hiPSC-derived cell types for drug screening.…”
mentioning
confidence: 99%
“…The minireviews in the series cover topics including the use of differentiated cells derived from induced pluripotent stem cells (iPSCs), 2 such as heart cells (cardiomyocytes), in toxicity assays with new or existing therapeutics and the use of iPSCderived cells for drug screening both for new drug candidates and repurposing of existing drugs. Three minireviews focus on the problems of using iPSC-derived cells in regenerative medicine: immune issues for autologous therapy will be considered in one minireview; the issue of genetic instability in iPSCs and iPSC-derived cells will be considered in the second; and preclinical studies with iPSCs and iPSC-derived cells will be discussed.…”
mentioning
confidence: 99%